Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,127.27 35.75 1.16%
FTSE 100 6,575.89 34.28 0.52%
DAX 9,273.01 99.30 1.08%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Financial Results Schedules, Discontinuation of Phase 3 Trial, Data Presentations, Strategic Alliances, and Premarket Filings -



     Financial Results Schedules, Discontinuation of Phase 3 Trial, Data
Presentations, Strategic Alliances, and Premarket Filings - Research Report on
                Biogen, Ariad, BioMarin, Alnylam, and Sequenom

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, October 23, 2013

NEW YORK, October 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Biogen
Idec Inc. (NASDAQ: BIIB), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), BioMarin
Pharmaceutical Inc. (NASDAQ: BMRN), Alnylam Pharmaceuticals, Inc. (NASDAQ:
ALNY), and Sequenom Inc. (NASDAQ: SQNM). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Biogen Idec Inc. Research Report  

On October 7, 2013, Biogen Idec Inc. (Biogen) announced that it will release
its Q3 2013 financial results on Monday, October 28, 2013 before the opening
of financial market. The Company informed that it will also conduct a live
webcast of a conference call on the same day at 9:00 a.m. ET to discuss the
financial results. Biogen stated that the live webcast and an archived version
of the call will be available at the investor relations section of its website
for one month. The Full Research Report on Biogen Idec Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/b95b_BIIB]

--

Ariad Pharmaceuticals Inc. Research Report

On October 18, 2013, Ariad Pharmaceuticals, Inc. (Ariad) announced the
discontinuation of its Phase 3 Evaluation of Ponatinib versus Imatinib in
Chronic Myeloid Leukemia (EPIC) trial of Iclusig (Ponatinib) in patients with
newly diagnosed chronic myeloid leukemia. According to the Company, the EPIC
trial was a randomized, two-arm, multicenter trial that sought to compare the
efficacy of ponatinib with that of imatinib in adult patients with newly
diagnosed CML in the chronic phase. According to Ariad, the Company and the
U.S. Food and Drug Administration have mutually agreed to terminate the trial
due to arterial thrombotic events that were observed in patients treated with
Iclusig. The Company added that the trial termination decision was made in the
interest of patient safety based on a recent assessment of data in the
clinical trial. The Full Research Report on Ariad Pharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/161c_ARIA]

--

BioMarin Pharmaceutical Inc. Research Report

On October 20, 2013, BioMarin Pharmaceutical Inc. (BioMarin) announced that
the Company is presenting five data presentations on its BMN 673 at the 2013
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics in Boston, being held from October 19 to October 23, 2013.
BioMarin informed that the research as reported on the poster concluded that
BMN 673 was approximately 100-fold more potent than olaparib and rucaparib at
trapping PARP, making it the most potent clinical PARP inhibitor to date with
the highest efficiency at trapping PARP-DNA complexes. "We believe PARP
trapping seen with BMN 673 is differentiating because BMN 673 appears to be
significantly more lethal to cancer cells than olaparib and rucaparib, and
PARP trapping may explain why BMN 673 shows far greater potency," said Hank
Fuchs, M.D., Chief Medical Officer at BioMarin. "We're looking forward to
further studies in gBRCA metastatic breast cancer patients to confirm and
extend the early clinical results of the compound." The Full Research Report
on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9b6c_BMRN]

--

Alnylam Pharmaceuticals, Inc. Research Report

On October 9, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that its
strategic alliance with The Medicines Company has produced a lead Development
Candidate that is a subcutaneously administered RNAi therapeutic (ALN-PCSsc)
targeting PCSK9 for the potential treatment of hypercholesterolemia. John
Maraganore, PhD, CEO of Alnylam said, "We have rapidly advanced the ALN-PCS
collaboration to reach our first goal, which was to designate our Development
Candidate by the end of this year. We anticipate submitting an investigative
new drug application for ALN-PCSsc with the US Food and Drug Administration in
late 2014. This is an important program within our 'Alnylam 5x15' product
development and commercialization strategy focused on RNAi therapeutics
directed toward genetically validated targets." The Full Research Report on
Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/5b29_ALNY]

--

Sequenom Inc. Research Report

On October 2, 2013, Sequenom, Inc. (Sequenom) announced its filing of
Premarket 510(k) Notifications to the United States Food and Drug
Administration (FDA) for its IMPACT Dx™ System and its IMPACT Dx™ Factor V
Leiden and Factor II Genotyping Test. According to the Company, the system and
test are intended for use in the clinical laboratory setting.  The Company
also informed that in anticipation of applying the CE mark for the IMPACT Dx
System, Sequenom has also received ISO 13485:2003 and EN ISO 13485:2012
certification for its quality management system. The Company added that it is
finalizing plans to commercialize the IMPACT Dx System in a number of European
countries that require CE marking. Michael Monko, Senior Vice President,
Genetic Analysis at Sequenom said, "The submission of our premarket
notifications is a tremendous achievement that we believe contributes
significant value to our Genetic Analysis business segment and represents the
transition of our proven research-use-only MassARRAY® System into the clinical
diagnostics arena." The Full Research Report on Sequenom Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/d291_SQNM]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement